All Pathways
GastroenterologyManagement

Hepatic Encephalopathy Management (AASLD/EASL 2022)

Hepatic Encephalopathy Management (AASLD/EASL 2022): Suspected Hepatic Encephalopathy → Confirm HE Diagnosis → Grade HE Severity (West Haven) → Grade 1:...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Suspected Hepatic Encephalopathy

    Patient with chronic liver disease + altered mental status/neurological changes

    1. Action

      Confirm HE Diagnosis

      Rule out other causes of altered mental status

      • Known chronic liver disease/cirrhosis
      • Assess for precipitants
      • Rule out: hypoglycemia, electrolyte disorders, infection, intracranial pathology, drugs/toxins
      • CT head if focal neuro signs or no improvement
      1. Decision

        Grade HE Severity (West Haven)

        Determine grade to guide management intensity

        • Covert HE: Grade 0-1 (psychometric testing abnormal)
        • Overt HE: Grade 2-4 (clinically apparent)
        1. Action

          Grade 1: Trivial Lack of Awareness

          Shortened attention, sleep disturbance

          • May have asterixis on exam
          • Start lactulose
          • Identify precipitants
          1. Action

            Identify & Treat Precipitants

            Most episodes have identifiable trigger

            • Infection (UTI, SBP, pneumonia) - start antibiotics
            • GI bleeding - treat source
            • Constipation - lactulose
            • Electrolyte disorders (hyponatremia, hypokalemia) - correct
            • Dehydration - IV fluids cautiously
            • Medications (opioids, benzos) - discontinue
            • Dietary protein excess - rare, don't restrict protein
            1. Action

              Lactulose (First-Line)

              Non-absorbable disaccharide

              • Initial: 25-45 mL PO q1-2h until bowel movement
              • Maintenance: 25-45 mL PO BID-QID
              • Target: 2-3 soft BM/day
              • Lactulose enema: 300 mL in 1L water (retain 30-60 min)
              1. Action

                Add Rifaximin (Second-Line)

                For lactulose failure or recurrence prevention

                • 550 mg PO BID
                • Continue lactulose (combination therapy)
                • Reduces HE recurrence by ~50%
                • No significant resistance or systemic absorption
                1. Decision

                  Assess Response

                  Improvement expected within 24-48 hours

                  1. Outcome

                    HE Resolved

                    Continue secondary prophylaxis

                    • Lactulose maintenance (2-3 BM/day)
                    • Rifaximin 550 mg BID after first overt HE episode
                    • Optimize nutrition (1.2-1.5 g/kg protein)
                    • Avoid precipitants
                  2. Warning

                    Refractory HE

                    Consider additional interventions

                    • Re-evaluate for missed precipitants
                    • Consider TIPS occlusion if post-TIPS HE
                    • Liver transplant evaluation
                    • Zinc supplementation (if deficient)
                    • L-ornithine L-aspartate (LOLA) - limited evidence
        2. Action

          Grade 2: Disorientation, Lethargy

          Obvious personality change, inappropriate behavior

          • Asterixis present
          • Lactulose + precipitant treatment
          • Consider admission
        3. Warning

          Grade 3: Somnolent, Confused

          Arousable but marked confusion

          • Hospital admission required
          • Lactulose NG if unable to take PO
          • Close monitoring
        4. Warning

          ⚠️ Grade 4: Coma

          ICU admission, consider ALF evaluation

          • Intubate for airway protection
          • Rule out cerebral edema
          • Lactulose enemas if intubated
          • Consider transplant evaluation

Guideline Source

AASLD/EASL Practice Guideline on Hepatic Encephalopathy in Chronic Liver Disease

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • West Haven criteria are subjective
  • Ammonia levels do not correlate with severity
  • Lactulose dosing requires individualization
  • Rifaximin cost may limit access
  • Must rule out other causes of altered mental status

Applicable Regions

USEUGlobal

EU: EASL guidelines jointly developed

US: AASLD 2022 is current standard

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the Hepatic Encephalopathy Management (AASLD/EASL 2022)?

The Hepatic Encephalopathy Management (AASLD/EASL 2022) is a management clinical algorithm for Gastroenterology. It provides a structured decision tree to guide clinical decision-making, based on AASLD/EASL Practice Guideline on Hepatic Encephalopathy in Chronic Liver Disease.

What guideline is the Hepatic Encephalopathy Management (AASLD/EASL 2022) based on?

This algorithm is based on AASLD/EASL Practice Guideline on Hepatic Encephalopathy in Chronic Liver Disease (DOI: 10.1002/hep.32327).

What are the limitations of the Hepatic Encephalopathy Management (AASLD/EASL 2022)?

Known limitations include: West Haven criteria are subjective; Ammonia levels do not correlate with severity; Lactulose dosing requires individualization; Rifaximin cost may limit access; Must rule out other causes of altered mental status. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Hepatic Encephalopathy Management (AASLD/EASL 2022) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free